Please login to the form below

Not currently logged in
Email:
Password:

Hemlibra

This page shows the latest Hemlibra news and features for those working in and with pharma, biotech and healthcare.

Roche cites COVID-19 and biosimilars in Q2 decline

Roche cites COVID-19 and biosimilars in Q2 decline

Although sales of  Roche's newer drugs climbed by 37%, including haemophilia A treatment Hemlibra (emicizumab), multiple sclerosis therapy Ocrevus (ocrelizumab) and PD-1 inhibitor Tecentriq (atezolizumab), this was unable to ... In fact, uptake of both

Latest news

  • New data reinforces safety profile of Roche’s Hemlibra New data reinforces safety profile of Roche’s Hemlibra

    New data from a phase 3b study reinforces the safety profile of blockbuster haemophilia A treatment Hemlibra, according to Roche’s Genentech division. ... Further new interim data suggests that people on Hemlibra may also be able to undergo certain

  • Novo Nordisk hits pause on rival to Hemlibra for haemophilia Novo Nordisk hits pause on rival to Hemlibra for haemophilia

    Concizumab is a potential rival to Roche’s blockbuster Hemlibra (emicizumab), the first non-clotting factor therapy for haemophilia A to reach the market, although it targets a different part of ... Hemlibra meanwhile binds to activated Factor IX and

  • Roche posts minor sales miss in Q4 as biosimilar pressure grows Roche posts minor sales miss in Q4 as biosimilar pressure grows

    Schwan highlighted four of these newer Roche medicines as driving the sales growth, namely  Perjeta (pertuzumab) for HER2-positive breast cancer,   Ocrevus (ocrelizumab) for multiple sclerosis, haemophilia therapy  Hemlibra (emicizumab) and

  • Roche to close $4.3bn Spark deal after FTC clearance Roche to close $4.3bn Spark deal after FTC clearance

    Roche’s monoclonal antibody Hemlibra is a blockbuster treatment in the market, but Spark has a number of potentially transformative gene therapies for haemophilia A in the pipeline that, if approved, ... The FTC had also raised concerns in its

  • UK’s CMA clears Roche’s $4.3bn takeover of Spark UK’s CMA clears Roche’s $4.3bn takeover of Spark

    Regulators had been scrutinising the deal because Roche’s antibody drug Hemlibra (emicizumab) has been growing at an impressive rate since its launch last year, and is firmly on course to ... In a statement from the CMA, the antitrust authority said:

More from news
Approximately 16 fully matching, plus 29 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics